Diagnos Laboratorium Utama Stock Cash Per Share
| DGNS Stock | IDR 210.00 6.00 2.78% |
Diagnos Laboratorium Utama fundamentals help investors to digest information that contributes to Diagnos Laboratorium's financial success or failures. It also enables traders to predict the movement of Diagnos Stock. The fundamental analysis module provides a way to measure Diagnos Laboratorium's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diagnos Laboratorium stock.
Diagnos |
Diagnos Laboratorium Utama Company Cash Per Share Analysis
Diagnos Laboratorium's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Diagnos Laboratorium Cash Per Share | 42.24 X |
Most of Diagnos Laboratorium's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Diagnos Laboratorium Utama is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Diagnos Laboratorium Utama has a Cash Per Share of 42.24 times. This is much higher than that of the Healthcare sector and notably higher than that of the Diagnostics & Research industry. The cash per share for all Indonesia stocks is notably lower than that of the firm.
Diagnos Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diagnos Laboratorium's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diagnos Laboratorium could also be used in its relative valuation, which is a method of valuing Diagnos Laboratorium by comparing valuation metrics of similar companies.Diagnos Laboratorium is currently under evaluation in cash per share category among its peers.
Diagnos Fundamentals
| Return On Equity | 0.0603 | |||
| Return On Asset | 0.0297 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 967.86 B | |||
| Shares Outstanding | 1.25 B | |||
| Shares Owned By Insiders | 80.00 % | |||
| Price To Earning | 10.49 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 302.18 B | |||
| Gross Profit | 148.56 B | |||
| EBITDA | 19.21 B | |||
| Net Income | 64.3 B | |||
| Cash And Equivalents | 52.8 B | |||
| Cash Per Share | 42.24 X | |||
| Total Debt | 10.45 B | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 7.26 X | |||
| Book Value Per Share | 171.17 X | |||
| Cash Flow From Operations | 58.87 B | |||
| Earnings Per Share | 51.84 X | |||
| Number Of Employees | 568 | |||
| Beta | 0.89 | |||
| Market Capitalization | 302.5 B | |||
| Total Asset | 241.98 B | |||
| Z Score | 17.8 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 241.98 B |
About Diagnos Laboratorium Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diagnos Laboratorium Utama's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diagnos Laboratorium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diagnos Laboratorium Utama based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Diagnos Stock
Diagnos Laboratorium financial ratios help investors to determine whether Diagnos Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diagnos with respect to the benefits of owning Diagnos Laboratorium security.